France’s Booming Companion Animal Market — And What It Means for You

If you’re working in the French veterinary sector, one thing is clear: demand is not just growing, it’s accelerating.

France’s veterinary services market generated approximately USD 6.45 billion in 2024, and it’s projected to climb to more than USD 12.2 billion by 2033, expanding at a steady 7.3% CAGR. What’s driving this surge is the rapid growth in companion animals, particularly cats and dogs, with feline care standing out as a key area of opportunity.

Pet ownership continues to rise across the country, with more than 60% of French households owning a pet. Cats, in particular, are among the most common companions, with estimates approaching 15 million nationwide. This expanding feline population is not only increasing demand for veterinary services, but also raising expectations for more advanced, targeted treatments.

For compounding pharmacies, this creates a clear opening to step into a more strategic role by delivering specialised, precision-based therapies that align with modern veterinary care.

Veterinary Medicine Is Evolving — And Expectations Are Higher

Veterinary care in France has shifted significantly in recent years. Animals are living longer, diagnostics are becoming more sophisticated, and treatment approaches are becoming more proactive and clinically advanced.

The veterinary infectious disease diagnostics segment alone is expected to grow from around USD 105 million in 2024 to approximately USD 174 million by 2030, reflecting a strong 9% CAGR. At the same time, therapeutics continue to dominate the market, accounting for nearly 60% of total veterinary healthcare revenue.

Within this changing landscape, Feline Infectious Peritonitis (FIP) has become a focal point. Once widely regarded as a fatal condition, FIP is now increasingly treatable, fundamentally changing how veterinarians approach care and what pet owners expect in return.

GS-441524: A Proven Antiviral Changing Clinical Outcomes

GS-441524 is at the centre of this shift.

As a nucleoside analogue antiviral, it works by targeting viral RNA polymerase, an enzyme essential for viral replication. By interrupting this process, it effectively halts the progression of infection and allows the animal’s immune system to recover.

What makes GS-441524 particularly compelling is the growing body of clinical evidence supporting its use. Studies and field experience consistently report response rates exceeding 80% in treated FIP cases, with many cats showing clear signs of improvement within the first two weeks of therapy. Its effectiveness has been observed across both effusive and non-effusive forms of the disease, reinforcing its value as a versatile antiviral option.

For compounding pharmacies, this is more than a scientific breakthrough. It represents a tangible opportunity to deliver formulations that are not only in demand, but capable of making a measurable difference in patient outcomes.

Why Forward-Thinking Pharmacies Are Acting Now

In today’s competitive environment, pharmacies that thrive are those that anticipate clinical needs and respond with precision.

GS-441524 enables you to move beyond standard offerings and provide tailored antiviral formulations that directly support veterinary treatment protocols. It strengthens your role as a

trusted partner to veterinarians while helping you stand out in a market where quality, reliability, and expertise are increasingly valued.

This is no longer a niche product. As awareness and demand continue to grow, GS-441524 is quickly becoming a core component of advanced feline care.

Designed to Meet France’s High Regulatory Standards

Operating in France means operating at one of the highest regulatory levels in Europe. Quality, traceability, and GMP compliance are not optional—they are expected.

With more than 8,300 veterinary establishments across the country and a steadily expanding professional network, the pressure to deliver consistent, high-quality formulations continues to increase.

Sourcing GS-441524 as a GMP-grade active pharmaceutical ingredient, supported by full Certificates of Analysis and technical documentation, allows compounding pharmacies to meet these expectations with confidence. It ensures reproducibility, supports compliance, and provides the level of assurance that both regulators and veterinary professionals demand.

A Market Ready for Advanced Therapies

French pet owners are more engaged than ever in the health of their animals. Even though insurance coverage remains relatively low, at around 5 to 6 percent, there is a clear willingness to invest in advanced treatments when recommended by veterinarians.

This is particularly true for serious conditions like FIP, where effective antiviral options are now available. The combination of informed veterinarians and committed pet owners is driving demand for high-quality, science-based therapies, creating the ideal conditions for compounding pharmacies to expand their role.

Turn Demand Into Growth

GS-441524 offers more than clinical value. It provides a pathway for compounding pharmacies to grow strategically within a rapidly evolving market.

By incorporating this antiviral into your portfolio, you position your pharmacy at the forefront of modern veterinary care. You enhance your ability to support complex treatment protocols, deepen relationships with veterinary clinics, and differentiate your services in a meaningful way.

Take the Next Step

The science is established. The demand is rising. The opportunity is clear.

Now is the time to act.

Explore GS-441524 today and bring advanced antiviral compounding to the French veterinary sector with confidence. Contact MedicaPharma to secure your GMP-grade supply and support veterinarians with the precision and quality they expect.